A Phase 1 interventional study of BMS-986446 and Placebo in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Not yet recruiting. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the drug levels, immune response, safety and tolerability of BMS-986446 in healthy Chinese participants.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-986446
Other: Placebo
Specified dose on specified days
Also known as: PRX005, Moponetug
Specified dose on specified days
Maximum observed plasma concentration (Cmax)
Time frame: Up to Day 85
Time of maximum observed plasma concentration (Tmax)
Time frame: Up to Day 85
Area under concentration time curve from time 0 to time of last quantifiable concentration [AUC(0-T)]
Time frame: Up to Day 85
Geometric mean ratios of area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]
Time frame: Up to Day 85
Total body clearance in intravenous infusion (CLT)
Time frame: Up to Day 85
Volume of distribution of terminal phase in intravenous administration (Vz)
Time frame: Up to Day 85
Apparent terminal serum half-life [T-HALF]
Time frame: Up to Day 85
Number of participants with anti-drug antibody (ADA) formation
Time frame: Up to Day 85
Number of participants with adverse events (AEs)
Time frame: Up to approximately 85 days
Number of participants with vital sign abnormalities
Time frame: Up to approximately 85 days
Number of participants with 12-lead electrocardiogram (12-lead-ECG) abnormalities
Time frame: Up to approximately 85 days
Number of participants with physical examination abnormalities
Time frame: Up to approximately 85 days
Number of participants with body weight abnormalities
Time frame: Up to approximately 85 days
Number of participants with clinical laboratory abnormalities
Time frame: Up to approximately 85 days
Number of Participants with Treatment Emergent suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Time frame: Up to approximately 85 days
No study locations are listed for this record.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Start is estimated for Feb 2027; primary completion for Jul 2027, 5 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Moponetug